Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study
Abstract Immune checkpoint blockade‐related pneumonitis is a rare but potentially life‐threatening adverse effect, but its risk factors are not completely understood. This case‐control study was conducted to identify pneumonitis risk factors in patients treated with anti‐PD1 monoclonal antibodies (m...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.1579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850122677173354496 |
|---|---|
| author | Pengfei Cui Zhefeng Liu Guoqiang Wang Junxun Ma Yuanyu Qian Fan Zhang Chun Han Yaping Long Ye Li Xuan Zheng Danyang Sun Jing Zhang Shangli Cai Shunchang Jiao Yi Hu |
| author_facet | Pengfei Cui Zhefeng Liu Guoqiang Wang Junxun Ma Yuanyu Qian Fan Zhang Chun Han Yaping Long Ye Li Xuan Zheng Danyang Sun Jing Zhang Shangli Cai Shunchang Jiao Yi Hu |
| author_sort | Pengfei Cui |
| collection | DOAJ |
| description | Abstract Immune checkpoint blockade‐related pneumonitis is a rare but potentially life‐threatening adverse effect, but its risk factors are not completely understood. This case‐control study was conducted to identify pneumonitis risk factors in patients treated with anti‐PD1 monoclonal antibodies (mAbs), including all the patients who developed pneumonitis after anti‐PD‐1 mAbs treatment in the Cancer Center of the Chinese People's Liberation Army from September 2015 to September 2017. Two controls per case were matched according to a propensity‐score matching algorithm to account for confounding effects caused by individual baseline variables. Demographic and clinical information was obtained from medical records. In total, 55 cases and 110 controls were included in the study. No association was observed between smoking status or primary lung cancer and risk of pneumonitis. Significant risk factors for pneumonitis related to anti‐PD‐1 mAbs were prior thoracic radiotherapy, prior lung disease and combination therapy with odds ratios of 3.34 (1.51‐7.39), 2.86 (1.45‐5.64) and 2.73 (1.40‐5.31), respectively. The associations remained significant in the multivariable logistic regression model. The risk of pneumonitis induced by anti‐PD‐1 mAbs is associated with prior thoracic radiotherapy, prior lung disease, and combination therapy. Clinicians should monitor these features in patients receiving anti‐PD‐1 therapy to optimize clinical safety and efficacy. |
| format | Article |
| id | doaj-art-0e5ddbd92d8747d3887faed9beb057c8 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2018-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0e5ddbd92d8747d3887faed9beb057c82025-08-20T02:34:47ZengWileyCancer Medicine2045-76342018-08-01784115412010.1002/cam4.1579Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control studyPengfei Cui0Zhefeng Liu1Guoqiang Wang2Junxun Ma3Yuanyu Qian4Fan Zhang5Chun Han6Yaping Long7Ye Li8Xuan Zheng9Danyang Sun10Jing Zhang11Shangli Cai12Shunchang Jiao13Yi Hu14First Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaThe Medical Department 3D Medicines Inc. Shanghai ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaThe Medical Department 3D Medicines Inc. Shanghai ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaFirst Department of Medical Oncology Chinese PLA General Hospital Beijing ChinaAbstract Immune checkpoint blockade‐related pneumonitis is a rare but potentially life‐threatening adverse effect, but its risk factors are not completely understood. This case‐control study was conducted to identify pneumonitis risk factors in patients treated with anti‐PD1 monoclonal antibodies (mAbs), including all the patients who developed pneumonitis after anti‐PD‐1 mAbs treatment in the Cancer Center of the Chinese People's Liberation Army from September 2015 to September 2017. Two controls per case were matched according to a propensity‐score matching algorithm to account for confounding effects caused by individual baseline variables. Demographic and clinical information was obtained from medical records. In total, 55 cases and 110 controls were included in the study. No association was observed between smoking status or primary lung cancer and risk of pneumonitis. Significant risk factors for pneumonitis related to anti‐PD‐1 mAbs were prior thoracic radiotherapy, prior lung disease and combination therapy with odds ratios of 3.34 (1.51‐7.39), 2.86 (1.45‐5.64) and 2.73 (1.40‐5.31), respectively. The associations remained significant in the multivariable logistic regression model. The risk of pneumonitis induced by anti‐PD‐1 mAbs is associated with prior thoracic radiotherapy, prior lung disease, and combination therapy. Clinicians should monitor these features in patients receiving anti‐PD‐1 therapy to optimize clinical safety and efficacy.https://doi.org/10.1002/cam4.1579anti‐PD‐1case‐control studypneumonitisrisk factors |
| spellingShingle | Pengfei Cui Zhefeng Liu Guoqiang Wang Junxun Ma Yuanyu Qian Fan Zhang Chun Han Yaping Long Ye Li Xuan Zheng Danyang Sun Jing Zhang Shangli Cai Shunchang Jiao Yi Hu Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study Cancer Medicine anti‐PD‐1 case‐control study pneumonitis risk factors |
| title | Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study |
| title_full | Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study |
| title_fullStr | Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study |
| title_full_unstemmed | Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study |
| title_short | Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study |
| title_sort | risk factors for pneumonitis in patients treated with anti programmed death 1 therapy a case control study |
| topic | anti‐PD‐1 case‐control study pneumonitis risk factors |
| url | https://doi.org/10.1002/cam4.1579 |
| work_keys_str_mv | AT pengfeicui riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT zhefengliu riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT guoqiangwang riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT junxunma riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT yuanyuqian riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT fanzhang riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT chunhan riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT yapinglong riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT yeli riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT xuanzheng riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT danyangsun riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT jingzhang riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT shanglicai riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT shunchangjiao riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy AT yihu riskfactorsforpneumonitisinpatientstreatedwithantiprogrammeddeath1therapyacasecontrolstudy |